IMMUPHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.075 GBX | +2.72% |
|
+1.97% | +24.48% |
| Apr. 29 | Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director | CI |
| Apr. 02 | Immupharma jumps amid new IP strategy for P140 technology platform | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 118K 148K | Sales 2022 | - | Capitalization | 6.13M 7.67M |
|---|---|---|---|---|---|
| Net income 2021 | -8M -10M | Net income 2022 | -3M -3.75M | EV / Sales 2021 | 126 x |
| Net cash position 2021 | 1.65M 2.06M | Net cash position 2022 | 668K 834K | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.03
x | P/E ratio 2022 |
-1.46
x | Employees | 13 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.72% | ||
| 1 week | +1.97% | ||
| Current month | -2.35% | ||
| 1 month | -6.95% | ||
| 3 months | +52.01% | ||
| 6 months | +23.37% | ||
| Current year | +24.48% |
1 week
1.80
2.18
1 month
1.802.71
Current year
0.823.00
1 year
0.823.80
3 years
0.8210.90
5 years
0.8232.20
10 years
0.82193.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 15-09-29 | |
Timothy Franklin
COO | Chief Operating Officer | 60 | 20-10-31 |
Lisa Baderoon
BRD | Director/Board Member | 57 | 12-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 15-09-29 | |
Timothy Franklin
COO | Chief Operating Officer | 60 | 20-10-31 |
Lisa Baderoon
BRD | Director/Board Member | 57 | 12-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 2.075 | +2.72% | 1 025 009 |
| 24-05-07 | 2.02 | +6.32% | 2,307,592 |
| 24-05-03 | 1.9 | -6.86% | 1,925,128 |
| 24-05-02 | 2.04 | +0.25% | 477,122 |
| 24-05-01 | 2.035 | -4.24% | 686,119 |
Delayed Quote London S.E., May 08, 2024 at 11:35 am EDT
More quotes
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
Calendar
2024-05-11
- BIO Equity Conference
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.48% | 10.55M | |
| +22.09% | 46.4B | |
| -1.80% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +9.62% | 26.01B | |
| -19.41% | 19.52B | |
| +30.12% | 12.43B | |
| -0.23% | 12.18B | |
| -0.73% | 12.13B |
- Stock Market
- Equities
- IMM Stock